Tubulin inhibitors
The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.
1. Compound of formula (I):
wherein
R is H or an alkyl, alkenyl, alkynyl, CO-alkyl or heteroalkyl group, all of which may optionally be substituted;
R′ is H or an alkyl, alkenyl, alkynyl, CO-alkyl or heteroalkyl group, all of which may optionally be substituted;
R″ is a group of formula —CH 2 OH or
n is 0, 1, 2, 3, 4 or 5;
Y is independently optionally substituted alkyl, heteroalkyl, halogen, CN, NO 2 or OH;
or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.
2. Compound according to claim 1 wherein R is H or C 1 -C 6 alkyl.
3. Compound according to claim 1 , wherein R′ is —CO-alkyl, alkyl or heteroalkyl.
4. Compound according to claim 1 , wherein R″ is
5. Compound according to claim 1 , wherein R″ is CH 2 OH.
6. Compound according to claim 1 , wherein n is 0.
7. Compound according to claim 1 wherein R is C 1 -C 6 alkyl, R′ is —CO-alkyl or heteroalkyl, n is 0 and R″ is —CH 2 OH or
8. Compound according to claim 1 wherein R is methyl, R′ is acetyl, n is 0 and R″ is
9. Pharmaceutical composition containing a compound according to claim 1 and optionally one or more carriers or adjuvants.
10. A method for treating cancer comprising administering a compound of claim 1 to a subject in need thereof, thereby treating the subject's cancer.
11. A method for treating cancer comprising administering a pharmaceutical composition of claim 9 to a subject in need thereof, thereby treating the subject's cancer.